IMMUNOPRECISE ANTIBODIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 USD | 0.00% |
|
+2.40% | -25.15% |
Presenter SpeechMartin Gagel (Analysts)All right. Just some preliminary comments here, everyon...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.28
USD
Average target price
7
USD
Spread / Average Target
+446.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.15% | 33.68M | |
| -3.57% | 89.33B | |
| +4.08% | 41.19B | |
| -15.09% | 31.87B | |
| +53.68% | 24.52B | |
| -15.13% | 15.68B | |
| -8.63% | 12.34B | |
| -40.39% | 12.23B | |
| +6.22% | 8.83B | |
| -6.32% | 8.28B |
- Stock Market
- Equities
- IPA Stock
- News ImmunoPrecise Antibodies Ltd.
- Transcript : ImmunoPrecise Antibodies Ltd. - Special Call